Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON)

CUSIP: 254604101

Q3 2024 13F Holders as of 30 Sep 2024

Holder snapshot 7 signals
Share change
-582,543
Put/Call ratio
99%
SEC-reported price per share
$49.14
Number of holders
130
Value change
-$26,632,908
Number of buys
81
Open additional details 1 more signal available
Number of sells
37
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
37,778,373

Security key

254604101

Report period

Q3 2024

Institutions

130

Top holders

10

Ownership snapshot

Top reported holders of IRON - Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Paradigm Biocapital Advis...
Disclosed value leader
Paradigm Biocapital Advis...
Comparable rows
15/15
Latest evidence
30 Jun 2024
13F Lead comparable stake: 7.2% Showing 1-6 of 15 holder rows.

Quick read

Paradigm Biocapital Advisors LP leads the comparable SEC ownership view at 7.2%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Paradigm Biocapital Advisors LP's linked filing trail.
Comparable ownership Top 5
Paradigm Biocapital Advisors LP 7.2%
Atlas Venture Life Science Adviso... 6.6%
Bain Capital Life Sciences Invest... 4.8%
ORBIMED ADVISORS LLC 4.7%
WELLINGTON MANAGEMENT GROUP LLP 4.6%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Paradigm Biocapital Advisors LP
13F
Company
13F
7.2%
$121,901,640
2,704,718 shares
30 Jun 2024
Atlas Venture Life Science Advisors, LLC
13F
Company
13F
6.6%
$113,101,182
2,509,456 shares
30 Jun 2024
Bain Capital Life Sciences Investors, LLC
13F
Company
13F
4.8%
$80,933,776
1,795,735 shares
30 Jun 2024
ORBIMED ADVISORS LLC
13F
Company
13F
4.7%
$80,475,685
1,785,571 shares
30 Jun 2024
WELLINGTON MANAGEMENT GROUP LLP
13F
Company
13F
4.6%
$79,165,230
1,756,495 shares
30 Jun 2024
Frazier Life Sciences Management, L.P.
13F
Company
13F
4.6%
$79,090,368
1,754,834 shares
30 Jun 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
130
Shares
27,309,249
Rows available
130
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2024 vs Q2 2024 Across Filers

Q2 2024 holders
119
Q3 2024 holders
130
Holder diff
11
Investor Q2 2024 Shares Q3 2024 Shares Share Diff Share Chg % Q2 2024 value Q3 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .